14. The use of any one of the preceding claims, wherein 0.5 mg to 1.5 mg atrasentan, or a pharmaceutically acceptable salt thereof, is to be administered to the subject.

15. The use of claim 14, wherein 0.75 mg to 1.25 mg atrasentan, or a pharmaceutically acceptable salt thereof, is to be administered to the subject.

16. The use of claim 15, wherein 0.75 mg atrasentan, or a pharmaceutically acceptable salt thereof, is to be administered to the subject.

17. The use of any one of the preceding claims, further comprising the use of a statin in the manufacture of a pharmaceutical composition wherein the pharmaceutical composition is to be administered to the subject.

18. The use of any one of the preceding claims, wherein the subject is suffering from an illness selected from the group consisting of coronary heart disease, hypercholesterolemia, hyperlipidemia, nephropathy, chronic kidney disease, diabetes, and albuminuria.

19. The use of claim 18, wherein the subject is suffering from hypercholesterolemia.

20. The use of claim 18, wherein the subject is suffering from hyperlipidemia.

21. The use of claim 18, wherein the subject is suffering from diabetes.

22. The use of claim 21, wherein the subject is suffering from type 2 diabetes.